I’m not arguing with the science and potential of our drug. But 6.7c per share currently tells you what the current market values us at. If $2 to $5 a share was a slam dunk, don’t you think people with more knowledge than us wouldn’t be loading up until the valuation gap closed?
Sarepta’s debt is basically eventual equity in any case (convertible bonds - option on equity conversion without debt covenants).
I’m not arguing with the science and potential of our drug. But...
-
- There are more pages in this discussion • 635 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
